Literature DB >> 26456960

Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium.

Olga V Pankova1, Evgeny V Denisov2,3,4, Anastasia A Ponomaryova5,6, Tatiana S Gerashchenko5,7, Sergey A Tuzikov8, Vladimir M Perelmuter1,9.   

Abstract

Recurrences occur in 30 % of lung cancer patients after radical therapy; however, known prognostic factors are not always effective. In this study, we investigated whether the frequency of squamous non-small cell lung cancer (NSCLC) recurrence depends on the presence of reactive lesions in tumor-adjacent bronchial epithelium. Specimens of adjacent lung tissue from 104 patients with squamous NSCLC were used for the determination of basal cell hyperplasia (BCH) and squamous metaplasia (SM) and for the analysis of the expression of Ki-67, p53, Bcl-2, and CD138. We found that recurrence was observed in 36.7 % of patients with BCH combined with SM (BCH + SM+) in the same bronchus, compared with 1.8 % in patients with isolated BCH (BCH + SM-; odds ratio (OR) 31.26, 95 % confidence interval (CI) 3.77-258.60; p = 0.00002). The percentage of Ki-67-positive cells was significantly higher in BCH + SM+ than in BCH + SM- (34.9 vs. 18.3 %; effect size 2.86, 95 % CI 2.23-3.47; p = 0.003). P53 expression was also more significant in BCH + SM+ than in BCH + SM- (14.4 vs. 9.6 %; effect size 1.22, 95 % CI 0.69-1.76; p = 0.0008). In contrast, CD138 expression was lower in BCH + SM+ than in BCH + SM- (21.8 vs. 38.5 %; effect size -6.26, 95 % CI -7.31 to -5.22; p = 0.003). Based on our results, we concluded that the co-presence of reactive bronchial lesions is associated with the development of recurrent squamous NSCLC and may be a negative prognostic indicator. In addition, significant differences in Ki-67, p53, and CD138 expression exist between isolated BCH and BCH combined with SM that probably reflect part of biological differences, which could relate to the mechanism of lung cancer recurrence.

Entities:  

Keywords:  Hyperplasia; Immunohistochemistry; Lung cancer; Metaplasia; Recurrence

Mesh:

Substances:

Year:  2015        PMID: 26456960     DOI: 10.1007/s13277-015-4196-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

1.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

Authors:  William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

Review 2.  Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies.

Authors:  Rajendra Gharbaran
Journal:  Crit Rev Oncol Hematol       Date:  2014-12-18       Impact factor: 6.312

3.  Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy.

Authors:  S Bota; J B Auliac; C Paris; J Métayer; R Sesboüé; G Nouvet; L Thiberville
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

Review 4.  Natural history of bronchial preinvasive lesions.

Authors:  Taichiro Ishizumi; Annette McWilliams; Calum MacAulay; Adi Gazdar; Stephen Lam
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

5.  The natural course of preneoplastic lesions in bronchial epithelium.

Authors:  Roderick H Breuer; Arifa Pasic; Egbert F Smit; Esther van Vliet; Anton Vonk Noordegraaf; Elle J Risse; Pieter E Postmus; Thomas G Sutedja
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

Review 6.  Preinvasive lesions of the bronchus.

Authors:  Anindo K Banerjee
Journal:  J Thorac Oncol       Date:  2009-04       Impact factor: 15.609

7.  Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma.

Authors:  Lori Shah; Kristin L Walter; Alain C Borczuk; Steven M Kawut; Joshua R Sonett; Lyall A Gorenstein; Mark E Ginsburg; Kenneth M Steinglass; Charles A Powell
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

Review 8.  Pulmonary preneoplasia.

Authors:  Sanja Dacic
Journal:  Arch Pathol Lab Med       Date:  2008-07       Impact factor: 5.534

Review 9.  Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis.

Authors:  Vladimir Riabov; Alexandru Gudima; Nan Wang; Amanda Mickley; Alexander Orekhov; Julia Kzhyshkowska
Journal:  Front Physiol       Date:  2014-03-05       Impact factor: 4.566

10.  Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis.

Authors:  Katja Hattar; Katharina Franz; Michael Ludwig; Ulf Sibelius; Jochen Wilhelm; Jürgen Lohmeyer; Rajkumar Savai; Florentine S B Subtil; Gabriele Dahlem; Bastian Eul; Werner Seeger; Friedrich Grimminger; Ulrich Grandel
Journal:  Cancer Immunol Immunother       Date:  2014-09-04       Impact factor: 6.968

View more
  3 in total

1.  Intrathyroid cystic thyroglossal duct remnant and ectopic thymus: a fortuitous or development-related association?

Authors:  Adriana Handra-Luca; Shuanzeng Wei
Journal:  Surg Today       Date:  2018-02-19       Impact factor: 2.549

2.  Premalignant Changes in the Bronchial Epithelium Are Prognostic Factors of Distant Metastasis in Non-Small Cell Lung Cancer Patients.

Authors:  Olga V Pankova; Liubov A Tashireva; Evgeny O Rodionov; Sergey V Miller; Sergey A Tuzikov; Dmitry S Pismenny; Tatiana S Gerashchenko; Marina V Zavyalova; Sergey V Vtorushin; Evgeny V Denisov; Vladimir M Perelmuter
Journal:  Front Oncol       Date:  2021-11-10       Impact factor: 6.244

3.  Neoadjuvant chemotherapy combined with intraoperative radiotherapy is effective to prevent recurrence in high-risk non-small cell lung cancer (NSCLC) patients.

Authors:  Olga V Pankova; Evgeny O Rodionov; Sergey V Miller; Sergey A Tuzikov; Liubov A Tashireva; Tatiana S Gerashchenko; Evgeny V Denisov; Vladimir M Perelmuter
Journal:  Transl Lung Cancer Res       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.